scholarly journals Analyses of Multiple Factors for Determination of "Selected Patients" Who Should Receive Rechallenge Treatment in Metastatic Colorectal Cancer: a Retrospective Study from Turkey

2015 ◽  
Vol 16 (7) ◽  
pp. 2833-2838 ◽  
Author(s):  
Ersin Ozaslan ◽  
Ayse Ocak Duran ◽  
Oktay Bozkurt ◽  
Mevlude Inanc ◽  
Mahmut Ucar ◽  
...  
2020 ◽  
Vol 17 (3) ◽  
pp. 185-194
Author(s):  
Jared Freml ◽  
Thomas Delate ◽  
Jesus Hermosillo-Rodriguez

Aim: To describe pharmacogenomic tumor testing among patients with metastatic colorectal cancer. Methods: This was a retrospective study of patients with metastatic colorectal cancer diagnosed between 1 January 2014 and 30 June 2018. Patients were assessed for pharmacogenomic testing and appropriateness of chemotherapy use. Results: Overall, 112/167 (67.1%) patients had at least one of the three recommended pharmacogenomic tests and 41/167 (24.6%) had all tests. Twenty-four patients were treated with cetuximab with 8/167 (4.7%) identified as being treated with a RAS variant (n = 3) or incomplete testing (n = 5); thus, not in accordance with guidelines. Conclusion: Uptake of testing was variable but increased over time; however, a small proportion of patients received cetuximab with a variant or not all recommended tests being performed.


2018 ◽  
Vol 29 ◽  
pp. v78
Author(s):  
I. Ghanem ◽  
A. Viudez ◽  
E. García-Torralba ◽  
J. Torres-Tenor ◽  
A. Carmona ◽  
...  

2013 ◽  
Vol 31 (4) ◽  
pp. 1035-1043 ◽  
Author(s):  
Luca Moscetti ◽  
Fabrizio Nelli ◽  
Maria A Fabbri ◽  
Isabella Sperduti ◽  
Daniele Alesini ◽  
...  

2015 ◽  
Vol 33 (15_suppl) ◽  
pp. e14677-e14677
Author(s):  
Laetitia Mais ◽  
Matthieu Sarrabi ◽  
Françoise Desseigne ◽  
Pierre Guibert ◽  
Christine Castillo ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document